Longeveron Inc. (LGVN): Insider Trading, Congress Trades & Research | Tormere

LGVN

$1.78+0.00%visit website

Longeveron Inc.

Market Cap

$57M

Live price × SEC shares (Aug 6, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

-0.09

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

47.8

TTM to Jun 2026 · revenue

P/B

5.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	137	365	398	287	1,187
Cost of revenue	12	108	134	105	359
Gross profit	125	257	264	182	828
Research & development	3,852	2,720	2,319	3,194	12,085
Total operating expenses	7,435	5,656	5,039	6,353	24,483
Operating income	(7,310)	(5,399)	(4,775)	(6,171)	(23,655)
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(7,221)	(5,444)	(4,736)	(6,073)	(23,474)
EPS (basic) ($)	(0.39)		(0.19)	(0.19)	—
EPS (diluted) ($)	(0.39)		(0.19)	(0.19)	—
Weighted avg. shares (basic)	18,373,198		24,786,282	31,378
Weighted avg. shares (diluted)	18,373,198		24,786,282	31,378

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 22 more quarters, back to Mar 2020, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Longeveron Announces Engagement of Lucid Capital Markets

Yahoo · 2026-10-28

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Yahoo · 2026-10-26

Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome

Benzinga · 2026-10-26

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga · 2026-10-22

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Yahoo Finance · 2026-09-30

A preprint suggests a cell therapy may reduce brain inflammation in Alzheimer’s

Stock Titan · 2026-09-30

Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?

Yahoo Finance · 2026-09-22

LGVN Posts Disappointing Trial Results

Yahoo Finance · 2026-09-17

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Yahoo Finance · 2026-09-16

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Yahoo Finance · 2026-09-03

Longeveron Announces 1-for-10 Reverse Stock Split

Yahoo Finance · 2026-08-24

Longeveron (LGVN) Q2 2026 Earnings Call Transcript

Yahoo Finance · 2026-08-19

LGVN Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design

Stocktwits · 2026-05-08

A $30 Million Reason to Buy Penny Stock Longeveron Today

Yahoo Finance · 2026-03-11

Informational purposes only, not investment advice.